Complement-Targeted Therapeutics Market
Number of pages: 100 | Report Format: PDF | Published date: February 10, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
CAGR |
8.9% |
|
Base Year For Estimation |
2021 |
|
Forecast Year |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Disease Type, Distribution Channel, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global complement-targeted therapeutics market is expected to register a revenue CAGR of 8.9% during the forecast period from 2022 to 2030.
Complement-targeted Therapeutics Market Fundamentals
Complement-targeted therapeutics is an emerging field of medicine that involves drugs or treatments that focus on targeting the complement system, a part of the immune system, to treat various diseases. By targeting the complement system, researchers are able to create more specific therapies that are tailored to the individual needs of each patient and their specific condition. This approach allows for more personalized and effective treatment for a variety of diseases, including cancer and autoimmune disorders. Complement-targeted therapeutics have been shown to be effective in treating a variety of diseases, with promising results in clinical trials. As the field of complement-targeted therapeutics continues to develop, more effective treatments are expected to be available in the near future.
Companies operating in the global market are increasing investments in research and development activities to develop new treatments for various diseases, such as autoimmune disorders, inflammation, and some forms of cancer. The development of complement-targeted therapeutics is an active area of research, and many pharmaceutical companies and biotech firms are investing in this field.
The complement system is involved in the immune response to infections and plays a role in certain autoimmune and inflammatory disorders. By targeting the complement system, complement-targeted therapeutics aim to modulate the immune response and treat diseases, such as autoimmune disorders, inflammation, and some forms of cancer. The complement-targeted therapeutics include drugs that inhibit the activation of specific complement proteins, drugs that block the binding of complement proteins to target cells, and drugs that increase the degradation of complement proteins. These drugs are used to treat a wide range of diseases, including lupus, rheumatoid arthritis, age-related macular degeneration, and paroxysmal nocturnal hemoglobinuria (PNH).
Complement-targeted Therapeutics Market Dynamics
The rising prevalence of chronic diseases is the primary driving factor for the revenue growth of the global complement-targeted therapeutics market. For instance, according to WHO’s September 2022 factsheet, non-communicable disease kills around 41 million individuals every year. Moreover, increasing investments by major pharmaceutical companies to develop novel treatments and therapies for treating complement-mediated diseases have further accelerated the revenue growth of the global complement-targeted therapeutics market. The budding trend of personalized medicines and the development of complement-targeted therapeutics tailored to specific patient populations are driving market revenue growth. The growing awareness about complement-mediated diseases and the benefits of complement-targeted therapeutics are boosting market revenue growth. The market is also rising due to increasing number of biological drug studies and complement-targeted medication clinical trials.
The high cost of treatment, inadequate reimbursement, and limited numbers of approved drugs for the complement-mediated disease are the major restraints impeding market revenue growth.
Complement-targeted Therapeutics Market Ecosystem
The global complement-targeted therapeutics market has been analyzed from three perspectives: disease type, distribution channel, and region.
Complement-targeted Therapeutics Market by Disease Type
[8567456]
Based on disease type, the global complement-targeted therapeutics market is segmented into paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), sickle cell disease, and others.
The sickle cell disease segment accounted for the principal revenue share of the market in 2021, attributed to the rising prevalence of sickle cell disease. For instance, according to the Centers For Disease Control and Prevention’s May 2022 report, sickle cell disease affects around 100,000 Americans and is more often where malaria is or was often. Sickle cell disease is a genetic blood disorder that affects hemoglobin, the protein in red blood cells that carries oxygen to the body’s tissues. In people with sickle cell disease, hemoglobin molecules can form into rigid, sickle-shaped cells that can block blood flow and cause pain, organ damage, and other serious health problems. Sickle cell disease is caused by a mutation in the gene that provides instructions for making hemoglobin and is passed from parents to children through inheritance. These factors are expected to fuel revenue growth of the sickle cell disease segment.
Complement-targeted Therapeutics Market by Distribution Channel
Based on the distribution channel, the global complement-targeted therapeutics market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital pharmacies segment dominated the market with the largest revenue share in 2021, as hospital pharmacies play a crucial role in the distribution and dispensing of complement-targeted therapeutics to patients with complement-mediated diseases, such as PNH and aHUS. Hospital pharmacies are equipped with advanced technologies and processes to manage and dispense high-cost, specialized medications, including complement-targeted therapeutics. They also have trained and specialized personnel, including pharmacists and technicians, who are knowledgeable in the handling, storage, and dispensing of these drugs. Additionally, the growing trend of centralization and standardization of hospital pharmacy operations is also contributing to the revenue growth of this segment.
Complement-targeted Therapeutics Market by Region
Based on region, the global complement-targeted therapeutics market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America dominated the global complement-targeted therapeutics market in 2021, due to the expansion of the healthcare industry, the presence of key players in the market, and the rise in complement-mediated diseases. Additionally, there are several current research & development projects to complement medicines in the region, which are expected to inevitably spur regional revenue growth. For instance, in January 2023, NovelMed announced the experimental medicine M8074 had received USFDA approval, allowing the business to begin an effectiveness trial in patients with aHUS in the coming months. With aHUS being a rare disease with an unmet need, NovelMed developed its anti-Bb antibody (NM8074) to treat patients who have signs of treatment-related resistance or complement-mediated relapses. In healthy volunteers, NM8074 recently finished a Phase I study with no safety issues. To advance NM8074 through additional development and licensure in several rare disease areas, NovelMed is further looking for licensing, collaboration, and acquisition possibilities.
Complement-targeted Therapeutics Market Competitive Landscape
The prominent players operating in the global complement-targeted therapeutics market are:
Complement-targeted Therapeutics Market Strategic Developments
The complement-targeted therapeutics market is expected to register a revenue CAGR of 8.9% during the forecast period from 2022 to 2030.
The rising prevalence of chronic diseases, an increasing number of biological drug studies and complement-targeted medication clinical trials, the budding trend of personalized medicine, and the development of complement-targeted therapeutics are fueling revenue growth in the global market.
The sickle cell disease segment dominates the complement-targeted therapeutics market.
The high cost of treatment, insufficient reimbursement policies, and limited numbers of approved drugs for the complement-mediated disease are restricting the global market revenue growth to its full potential.
Vertex Pharmaceuticals, Alexion Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd., Creative Biolabs, and Biogen are among the top market players.
*Insights on financial performance are subject to availability of information in the public domain